shr-1802
mAbexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 10, 2020 (NCT04414150)
Timeline
Indications
Mechanism of action
- LAG3INHIBITOR
LAG3 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05794477 | Phase 1/Phase 2 (Phase 2) | Apr 28, 2023 | Hengrui Therapeutics, Inc. |
| NCT05208177 | Phase 2 | Apr 22, 2022 | Hengrui Therapeutics, Inc. |
| NCT04414150 | Phase 1 | Jun 10, 2020 | Hengrui Therapeutics, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hengrui Therapeutics, Inc. | For profit | 3 | 3 | 2 | 2020 |
1 organizations
Page 1 / 1